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The introduction and scale-up of combination antiretroviral therapy 
(cART) has resulted in a significant decrease in morbidity and 
mortality rates in children perinatally infected with HIV.[1,2] These 
children are now surviving into adolescence and adulthood with 
lifelong chronic HIV infection.[3] Challenges persist, however, in part 
owing to the limited availability of antiretroviral treatment options 
for paediatric patients.[4] Further, inequalities persist in the South 
African (SA) public sector healthcare system, and limited clinical 
HIV expertise remains a key concern.[5] In poorly resourced public 
sector settings in SA, with higher rates of virological failure[6-8] and 
longer duration of a failing regimen,[4,9,10] the emergence of drug 
resistance mutations poses a threat to future antiretroviral options.
SA national antiretroviral guidelines for the treatment of HIV-
infected children have evolved from cART initiation with stavudine 
(d4T) as part of the nucleoside reverse transcriptase inhibitor 
(NRTI) backbone to abacavir (ABC).[11] Single dose-ritonavir (RTV) 
was routinely prescribed to children aged <3 years for the first 
3 years of the antiretroviral roll-out programme in SA.[12] Prior 
exposure to RTV-based regimens has been reported to be associated 
with suboptimal treatment responses, thus increasing the risk of 
acquisition of protease inhibitor (PI) resistance mutations.[13] Boosted 
lopinavir (LPV) for children aged <3 years and efavirenz (EFV) 
for children aged >3 years has remained unchanged. A number of 
strategies, including lamivudine (3TC) monotherapy, have been 
widely employed to manage the complex adherence challenges in 
children failing first- or second-line therapy in the public sector 
setting. As a result, a large proportion of children are exposed to a wide 
array of antiretroviral agents with a potential of emergence of HIV 
drug resistance, resulting in limited options for the future. Access to 
salvage therapy in the SA public sector was implemented in 2015 by 
the National Department of Health and allows for construction of an 
appropriate regimen determined by an HIV genotype test.[11]
PIs are an important foundation for the management of HIV-
infected children in SA. The type of PI exposure and whether 
unboosted PIs are used influence HIV resistance PI mutations and 
patterns that emerge.[14] Despite the high genetic barrier of PIs, major 
PI resistance mutations have been reported in several SA studies 
(involving 89, 75 and 50 children), with frequencies of 6.3%, 10.7% 
and 14%, respectively.[14-16]
Objectives
The current study focuses on a group of heavily experienced 
children managed in the public sector with resource constraints, with 
virological failure of either first-line or second-line regimens, longer 
duration of a failing regimen, exposure to various treatment strategies 
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Background. Advances in HIV management have improved treatment outcomes in the HIV-infected population. However, these advances have 
not been without multifaceted challenges. In sub-Saharan Africa, their impact is reflected in the increased emergence of HIV drug resistance 
mutations. With the rise in exposure of children to protease inhibitors (PIs), the possibility of increasing PI resistance remains a concern.
Objectives. To describe a group of antiretroviral-experienced children with PI drug resistance mutations after failure on first- or second-line 
regimens in a public sector setting in South Africa.
Methods. This was a retrospective cohort study of 22 children perinatally infected with HIV who had HIV genotyping conducted between 
January 2011 and December 2017.
Results. Of the 236 children who had HIV genotyping conducted, 22 (9.3%) had evidence of HIV PI resistance mutations. Twenty-one 
of the 22 children (95.5%) had major mutations in the protease region of the HIV genome. Of these children, 66.7% (14/21) had loss of 
response to both boosted lopinavir and atazanavir, with boosted darunavir remaining susceptible in only 12 (57.1%). The most frequent 
major PI mutations were V82A (76.2%), M46I/M46L (76.2%), I54V (62.0%) and L76V (33.3%).
Conclusions. We observed a high rate of PI resistance mutations, with a resulting loss of PIs that could be used in construction of third-
line regimens. To build on improvements from the introduction of antiretroviral therapy, increased efforts are needed by both health 
professionals and caregivers to improve adherence measures in children perinatally infected with HIV.
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(DGMAH), a public sector hospital located outside Pretoria, SA. 
Approximately 2 200 children are actively managed in the DGMAH 
HIV paediatric clinic. Children are transferred to the adult HIV clinic 
on reaching the age of 16 years. The HIV package of care includes 
routine monthly clinic visits, follow-up CD4+ T-cell counts and HIV 
viral load (VL) testing, as well as safety bloods as defined by the SA 
National Antiretroviral Treatment Guidelines.[12] Ongoing academic 
research activities provided access to HIV genotyping for individuals 
with a VL >1 000 copies/mL. The majority of the paediatric attendees 
were initiated on an ABC with 3TC NRTI backbone with either EFV 
or boosted LPV depending on age. However, a number of children 
were initiated on treatment prior to 2010 and remained on d4T with 
3TC as part of the NRTI backbone. Enrolment of the cohort was 
through convenience sampling of children aged <16 years who had 
been on cART for ≥1 year, had developed virological failure, and 
had HIV genotyping conducted from January 2011 to December 
2017. Children with missing clinical files or HIV genotype reports 
conducted prior to 2011 were excluded from the cohort.
Ethical considerations
The Sefako Makgatho Health Sciences University Research and 
Ethics Committee approved collection of clinical and genotype data 
(ref. no. MREC/P/83/2009). Written informed consent was obtained 
from each child’s caregiver.
HIV genotyping
HIV genotyping was performed using an in-house drug resistance 
assay. Briefly, a 1.7 kb amplicon was generated by reverse transcriptase 
(RT)-initiated polymerase chain reaction of the entire protease (PR) 
and partial RT-coding regions. The amplicon was sequenced using 
five primers from codons 1 - 99 of PR and codons 1 - 230 of RT. 
Sequencing was performed with either an ABI PRISM 3730 or an ABI 
PRISM 3100-Avant Genetic Analyzer (Applied Biosystems, USA). To 
identify drug resistance mutations and predict drug susceptibility, 
the Stanford HIV Drug Resistance Database version 8.3 (Stanford 
University, USA) was used. Susceptibility to boosted LPV, atazanavir 
(ATV) and darunavir (DRV) was determined using the penalty score 
where, from the total score for each of the three PIs, five levels of 
inferred drug resistance were reported: susceptible, potential low-
level resistance, low-level resistance, intermediate resistance and 
high-level resistance.
Statistical analysis
Clinical baseline and demographic variables were compared using 
medians with interquartile ranges (IQRs) for numerical data or 
proportions for categorical data, with genotype data presented as 
proportions. A two-sided Fisher’s exact test was used to compare 
the association of categorical variables, and p-values <0.05 were 
considered statistically significant. Statistical analysis was performed 
using GraphPad Prism 6 (GraphPad Software, USA).
Results
Patient characteristics
Demographic and baseline clinical characteristics are presented in 
Tables 1 and 2. Of 236 children who had HIV genotyping conducted 
over the 6-year study period, 22 (9.3%) had evidence of PI HIV 
resistance mutations and were included in the study; 54.5% of all 
children were female. World Health Organization (WHO) clinical 
stage at cART initiation was III or IV in 91.0% of the children. WHO 
stage III was the most common stage at 77.2%, representing most of 
the children noted to have been placed on concurrent TB treatment at 
cART initiation. The median age at initiation was 3 years (IQR 1.25 - 
8.6), with most of the children (45.5%) initiating cART between the 
ages of 0 and 3 years and ~14% at an advanced age of 10 - 16 years. 
All children were documented to have been infected perinatally. Prior 
to treatment initiation, 40.9% of children had laboratory evidence of 
severe immunosuppression, with CD4+ T-cell percentages between 
0% and 10%. Review of CD4+ T-cell absolute counts revealed that 
27.3% had CD4+ T-cell counts <100 cells/µL. Overall, the median 
duration of a failing regimen was 22 months (IQR 6 - 66), and the 
median VL at genotype was 4.5 log10 copies/mL.
Virological failure
The median age of all 22 children at genotyping was 8 years 
(IQR 4.35 - 11.7), with a duration of 22 months on a failing regimen. 
The median HIV VL at failure was 4.52 log10 (IQR 3.38 - 4.8). All 
22 children with PI resistance mutations had been on a boosted LPV 
regimen at the time of genotyping. The predominant NRTI backbone 
in use in this cohort was zidovudine (AZT) with 3TC (n=7, 31.8%) 
and ABC with 3TC (n=7, 31.8%). The remaining children were on 
AZT with ABC (n=5, 22.7%) and d4T with 3TC (n=3, 13.6%). In 
addition, 6 of the children (22.3%) had prior exposure to single-dose 
RTV for a median duration of 3 months as well as 3TC monotherapy 
as a holding regimen.
Drug resistance mutations
All genotyped samples belonged to HIV subtype C. Twenty-one 
of the 22 children (95.5%) had major mutations in the PR region. 
The distribution of all PI mutations is reflected in Figs 1 and 2. 
The most frequently occurring major PI mutations were V82A 
(76.2%), I54V (62.0%), M46I (52.4%), L76V (33.3%) and M46L 
(23.8%). The remaining major PI mutations I47A, I84V and V32I 
were detected at frequencies of 9.5%, 4.7% and 4.7%, respectively. 
The median number of major PI mutations was 3 (IQR  2 - 4), with 
the predominance of 3 mutations seen in 6 children. The major 
LPV resistance mutations detected were M46I, L76V and V82A, 
occur ring alone or in combinations of up to 5 mutations in 
7 children. Fourteen of the 21 children with major mutations (66.7%) 
experienced loss of activity to both boosted LPV and ATV. However, 
boosted DRV remained susceptible in 12 (57.1%).
Mutations classified as ‘accessory’ PI resistance mutations by 
the IAS (International Antiviral Society)-USA were detected in 
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Fig. 1. Overall distribution of major and accessory PI mutations. (PI = 
protease inhibitor).
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polymorphic accessory mutation exclusively. 
‘Other’ PI mutations A71V and L10V were 
observed with a frequency of 2 each. Further 
analysis of children with prior exposure 
to RTV revealed no association between 
duration of single-dose RTV and emergence 
of PI mutations (p=0.275). There was no 
association between duration of a failing 
regimen (<2 years v. >2 years on failing 
regimen) and the emergence of additional 
PI mutations (p=0.6032).
The most common NRTI mutation 
was the M184V mutation, detected at a 
frequency of 17 (77.3%). L74V and L74I  – 
both with compensatory effects on viral 
fitness – were detected in children on ABC, 
with a frequency of 2 (9.1%) and 1 (4.5%), 
respectively. The combination of L74V plus 
M184V occurred in 3 children (13.6%) in our 
cohort. Viruses carrying the K65R resistance 
mutation were observed in only 3 children 
(13.6%). Of interest is that none of these 
children were documented to have been 
on tenofovir disoproxil fumarate (TDF), 
but all had exposure to ABC at the time 
of HIV genotyping. Thymidine analogue 
mutations (TAMs) were observed in 63.6% 
of the children, with 4 (18.2%), 3 (13.6%) 
Table 1. Demographic and clinical data on HIV perinatally infected children with PI resistance mutations
Characteristic All children (N=22 )
Gender female, n (%) 12 (54.5)
Age at cART initiation (years), median (IQR) 3 (1.25 - 8.6) 
Age categories (years), n (%)
0 - 3 10/20 (50.0)
3.1 - 5 2/20 (10.0)
5.1 - 10 5/20 (25.0)
10.1 - 16 3/20 (15.0)
Unknown 2 (9.1)





TB treatment history, n (%)
Yes 14 (63.6)
No 8 (36.4)
Nadir CD4+ T-cell count (cells/µL), median (IQR) 289 (94 - 687) 
CD4+ T-cell count categories (cells/µL), n (%)
<50 4 (21)
50 - 100 2 (10.5)
101 - 200 1 (5.3)
201 - 300 3 (15.8)
301 - 500 1 (5.3)
501 - 1 000 7 (36.8)
>1 000 1 (5.3)
Unknown 3 (13.6)
Nadir CD4+ T-cell percentage (cells/µL), median (IQR) 10.3 (1.97 - 17.5)
CD4+ T-cell percentage, n (%)
0 - 10 9 (47.3)
11 - 20 9 (47.3)
20 - 30 1 (5.3)
30 - 50 0
Unknown 3 (13.6)





























































S PLR       LLR           IR           HLR
Fig. 2. Proportions of children with S PIs (penalty score <10) and PLR (penalty score 10 - 14), LLR 
(penalty score 15 - 29), IR (penalty score 30 - 59) and HLR (penalty score >60). (PI = protease inhibitor; 
S = susceptible; PLR = potential low-level resistance; LLR = low-level resistance; IR = intermediate 
resistance; HLR = high-level resistance; r=ritonavir.)
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and 6 (27.3%) harbouring 1, 2 and ≥3 TAMs, respectively. A distinct 
TAMs 1 pathway pattern was detected in 3 patients, with the rest 
displaying overlapping TAMs 1 and 2 pathways. Non-nucleoside 
reverse transcriptase inhibitor (NNRTI) mutations were detected 
in 14 children (63.6%), at the following frequencies: K103N n=5, 
22.7%; V106M n=3, 13.6%; G190A n=5, 22.7%; Y188C/L n=5, 22.7%; 
and E138A/Q n=2, 9.1%. Cross-level resistance to first-generation 
NNRTIs was evident in 12 of these children (85.7%), with only 7 of 
them remaining fully susceptible to etravirine, a second-generation 
NNRTI often used for construction of salvage therapy.
Discussion
With high levels of virological failure in our cohort, convenience 
sampling of 236 children for HIV genotyping was conducted over 
a 6-year period. We focused on the 9.3% (22/236) who displayed PI 
resistance mutations and were on PIs at the time of HIV genotyping. 
Our findings of increasing PI resistance mutations are consistent 
with other SA studies of similar size conducted between 2000 and 
2012, in which rates of PI resistance mutations were 6.3%,[15] 10.7%[14] 
and 14%.[16] However, another study reported a high prevalence of 
major PI mutations (49%)[17] in a public sector setting in SA.
Baseline clinical information on the study participants reflects a 
pattern consistent with poor outcomes.[18] While the overall median 
age of initiation of cART was 3 years, 13.6% of the children were 
initiated at ages between 10 and 16 years and 91.0% were clinically 
staged as WHO III or IV. In addition, 40.9% of the children had 
a nadir CD4+ T-cell percentage between 0% and 10%. It has been 
suggested and shown that a low CD4+ T-cell count may be associated 
with an increased probability of virological failure on PI-based 
regimens.[19-21]
A factor contributing to the emergence of major PI resistance 
mutation is prior exposure to an unboosted PI during ongoing 
viraemia.[17,22,23] With the SA national antiretroviral treatment 
guidelines in the past (2004 - 2007) having advocated full-dose RTV 
in children aged <6 months and those on concomitant rifampicin-
based antituberculosis therapy,[12] 6 (27.3%) of the children in our 
cohort with major PI mutations had been on full-dose RTV. Similar 
findings from a number of small studies of children on full-dose 
RTV support the development of major PI resistance mutations, with 
reported rates of 37.1%,[24] 50%[18] and 72%.[14] However, the high 
proportion of children with major PI-associated resistance mutations 
in our cohort (95.5%) cannot be explained by prior use of RTV alone. 
Three of the 21 children with major PI mutations (14.3%) also had 
natural polymorphisms that on their own would not be expected to 
affect the efficacy of boosted PIs.[25-27]
Knowledge of the effect of various HIV resistance mutations 
on antiretroviral susceptibility can facilitate selection of the most 
active second- or third-line regimen, especially if options involving 
other classes of drugs have been exhausted. In our cohort, major PI 
mutations were detected at a high rate of 95.5%, resulting in 66.7% 
of children losing activity of both boosted LPV and ATV, with 12 
(57.1%) remaining fully susceptible to second-generation DRV. 
V82A – a non-polymorphic mutation selected primarily by boosted 
LPV – was one of the most frequently occurring PI mutations in this 
cohort, detected in 76.2% of the children with major PI mutations. 
Emergence of V82A resulted in loss of activity of boosted LPV 
with cross-level resistance to boosted ATV.[28-30] However, L76V, a 
PI mutation selected for by LPV and DRV,[31,32] was observed in 7 
(33.3%) of these children, resulting in loss of activity of both boosted 
LPV and DRV. The presence of the major PI mutations with resulting 
loss to both LPV and ATV, as well as DRV, accessible only through 
the SA National Department of Health third-line committee as part 
of salvage therapy, remains a serious concern. The fact that none of 
the children in our cohort were presented to the third-line committee 
Table 2. Profile of HIV perinatally infected children at genotyping 
Characteristic All children (N=22)
Age (years), median (IQR) 8 (4.35 - 11.7) 
Age categories (years), n (%)
0 - 3 1 (5)
3.1 - 5 6 (30)
5.1 - 10 7 (35)
10.1 - 16 6 (30)
Unknown 2 (9.1)
CD4+ T-cell percentage, median (IQR) 18.7 (14 - 23.7) 
CD4+ T-cell percentage, n (%)
0 - 10 3 (16.7)
11 - 20 7 (38.9)
21 - 30 6 (33.3)
>30 2 (11.1)
Unknown 4 (18.2)
VL (log10 copies/mL), median (IQR) 4.52 (3.38 - 4.8) 
Duration of cART (years), median (IQR) 3 (0.95 - 6.94) 
Duration of failing therapy (VF) (months), median (IQR) 22 (6 - 66) 
ART regimens, n (%)
AZT, 3TC, LPV/r 7 (31.8)
d4T, 3TC, LPV/r 3 (13.6)
AZT, ABC, LPV/r 5 (22.7)
ABC, 3TC, LPV/r 7 (31.8)
IQR = interquartile range; VL = viral load; cART = combination antiretroviral therapy; VF = virological failure; AZT = zidovudine; d4T = stavudine; ABC = abacavir; 3TC = lamivudine;  
LPV/r = lopinavir/ritonavir.
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highlights the need for increased awareness of availability of access 
to this committee.
Study limitations
A limitation of this study is the fact that it was conducted at a single 
site, an academic hospital, so the findings may not be generalisable to 
other settings. The small cohort size also means that caution should 
be exercised when interpreting these findings, and a study with a 
much larger cohort may be needed to corroborate the findings.
Conclusions
Despite gains made in HIV management, HIV resistance continues to 
be a significant challenge in HIV-infected children, limiting current 
and future options. Of concern is the loss of antiretroviral agents 
typically used to construct a regimen for salvage therapy and the 
fact that none of the children in the study had accessed third-line 
committee-recommended therapy.
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